OMEROS CORP
OMER · XNASCIK 1285819fmd_0EEAQ0K47J3SXG7WWH3YKYWCREManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 42 | 65 | 30 | 112 | 74 | – | – | – | – | – |
| Cost of revenue | 1 | 1 | 1 | 1 | 1 | – | – | – | – | – |
| Gross profit | 40 | 64 | 29 | 111 | 73 | – | – | – | – | – |
| Research and development | 51 | 56 | 90 | 106 | 108 | 119 | 113 | 115 | 120 | 81 |
| Selling, general and administrative | – | – | – | – | – | 55 | 51 | 50 | 47 | 42 |
| Total operating expenses | 96 | 109 | 142 | – | – | – | – | – | – | – |
| Operating income | (54) | (44) | (112) | (146) | (157) | (174) | (163) | (165) | (167) | (123) |
| Interest expense | 8 | 11 | 16 | 23 | 27 | 20 | 23 | 31 | 25 | (1) |
| Interest and investment income | – | – | – | – | 1 | 2 | 2 | 15 | 8 | 2 |
| Other non-operating income (expense) | 1 | 1 | 2 | 2 | 1 | 2 | – | – | – | – |
| Income before taxes | (67) | (53) | (140) | (167) | (196) | (192) | (182) | (175) | (180) | (3) |
| Income tax expense | 0 | 0 | (13) | (20) | (23) | 0 | 0 | 0 | 2 | 2 |
| Net income from continuing operations | (67) | (53) | (127) | (147) | (173) | (192) | (182) | (175) | (183) | (5) |
| Net income | (67) | (53) | (127) | (84) | (138) | 194 | 47 | (118) | (157) | (3) |